<DOC>
	<DOCNO>NCT00040521</DOCNO>
	<brief_summary>The purpose study assess activity multiple dose oral rhIL-11 patient active Crohn 's disease ( Crohn 's Disease Activity Index [ CDAI ] score 220-400 ) .</brief_summary>
	<brief_title>Study Evaluating rhIL-11 Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<criteria>Documented , sign date informed consent participate trial prior study related procedure perform . Men woman age 16 year . Diagnosis Crohn 's disease least 6 month appropriately document confirmed radiological study , endoscopy ( histological examination prefer ) , surgical pathology ( Patients diagnosis Crohn 's disease le 6 month may include diagnosis confirm biopsy characteristic Crohn 's disease ) Use follow medication within specified time period prior randomization : Nonsteroidal antiinflammatory drug ( NSAIDs ; include Cyclooxygenase2 [ COX2 ] inhibitor &gt; 500 mg/day acetylsalicylic acid ) Codeinecontaining compound Corticosteroid enema</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Active Crohns Disease</keyword>
</DOC>